The effects of Dabrafenib, Trametinib and their combination on stably transfected BEAS-2B cells. A. Both G469S-BRAFand D594E-BRAF/CRAF stable transfectants showed increased viability compared to respectively WT-BRAF (30 ± 11%) and WT-BRAF/CRAF (31 ± 18%) stable-transfectants. However as wild-type and mutant recombinant genes are expressed at significantly different levels in the transfected clones (S.2 C), one cannot exclude that some of the differences in viability could be due to different expression levels of recombinant proteins (wild-type vs. mutant). B. Cells were incubated for 2 days with monotherapy or combined treatment with Dabrafenib (2.5 μM) and Trametinib (25 nM). Viability was measured, and relative viability was determined by normalizing to the vehicle group. Means ± SEM are from two independent experiments, each performed in quadruplicate. C. BEAS-2B stable transfectants were lysed and subjected to western blot analysis to determine the expression of the transfected genes.
